Jeff Evanson

Mr. Evanson has served as Chief Commercial Officer since November 2018. Mr. Evanson joined Outlook Therapeutics from Scott Three Consulting where he was the Founder and President. Previously he was a Managing Director in the Life Science Practice of Navigant from 2014 to 2018. He joined the firm in September of 2014 from Novartis (Alcon) where he was the Vice President and Global Commercial Head of the Pharmaceutical Franchise. During his time at Alcon, he was responsible for all aspects of strategy, portfolio (both internal and external opportunities), global brands, launches and campaigns. Mr. Evanson has extensive experience with the ophthalmology and retina landscape including sustained delivery, drug/device combination and diagnostics within the dry eye, glaucoma, retina and allergy eye health markets.

Prior to Novartis, Mr. Evanson spent 10 years at Medtronic in a variety of pre-commercialization and post-commercialization roles. He has led programs from Opportunity Assessment through to Global Launch Plans and Life Cycle Management. These responsibilities allowed Mr. Evanson direct experience with the US FDA and the US Centers for Medicare and Medicaid Services. Mr. Evanson also has experience in Pharmaceutical Sales and Sales Training.

Jeff received his MBA from the University of Minnesota (2001) and a BA in Chemistry from the University of St. Thomas in St. Paul Minnesota (1991). He served as a two-term Board Member of Gillette Children’s Hospital in St. Paul, Minnesota, from 2008 to 2014 and currently is on the Board of Directors of Children’s HeartLink.